BCMA
Assets acting on this target.
- Class
- BCMA-directed therapy (B-cell maturation antigen)
- Pathway
- Fully human anti-BCMA scFv (25C2) with CD8α hinge/transmembrane domain, 4-1BB costimulatory domain and CD3ζ signaling domain; NMPA-approved Feb 2024 for relapsed/refractory multiple myeloma (China)
B-cell maturation antigen (BCMA), also known as TNFRSF17, is a cell-surface receptor expressed almost exclusively on mature B lymphocytes and, at high density, on plasma cells, the antibody-producing cells that become malignant in multiple myeloma. BCMA binds two ligands, APRIL and BAFF, and this engagement drives downstream NF-κB signaling that supports plasma cell survival and proliferation. Because malignant plasma cells depend heavily on this survival signal and display BCMA uniformly, the receptor serves as a distinguishing marker that can be exploited therapeutically, largely independent of the survival pathway itself. Chimeric antigen receptor (CAR) T-cell therapy re-engineers a patient's own T lymphocytes to express a synthetic receptor whose extracellular portion recognizes BCMA and whose intracellular portion triggers T-cell activation, bypassing the need for conventional antigen presentation. This allows the engineered T cells to recognize and eliminate BCMA-bearing tumor cells directly. The broader disease relevance of BCMA-directed therapy spans multiple myeloma and, in principle, other plasma-cell and B-cell disorders where this receptor is expressed, making it one of the most actively pursued targets across cellular, antibody-conjugate, and bispecific antibody modalities.
By indication
Related mechanisms
BCMA drugs compared
30 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Belantamab mafodotin | GlaxoSmithKline | antibody-drug conjugate (anti-BCMA, MMAF payload) | Approved | Approved in Multiple Myeloma |
| Ciltacabtagene autoleucel | Johnson & Johnson, Legend Biotech Corporation | CAR-T (autologous cellular therapy) | Approved | Approved in Multiple Myeloma |
| Idecabtagene vicleucel | Bristol-Myers Squibb | cell therapy (autologous CAR-T) | Approved | Approved in Multiple Myeloma |
| Anitocabtagene autoleucel | Gilead Sciences | CAR-T (autologous cellular therapy) | Phase 3 | Phase 3 in Multiple Myeloma |
| Equecabtagene autoleucel | IASO Biotherapeutics | CAR-T cell therapy (fully-human anti-BCMA) | Phase 3 | Phase 3 in Multiple Myeloma |
| Hrain anti-BCMA CAR-T | Hrain Biotechnology Co., Ltd. | cell therapy (autologous BCMA-targeted CAR-T) | Phase 2 | Phase 2 in Multiple Myeloma |
| HRC0202 | Hrain Biotechnology Co., Ltd. | CAR-T (autologous, BCMA-directed) | Phase 2 | Phase 2 in Multiple Myeloma |
| AZD4045 | AstraZeneca | allogeneic CAR-T cell therapy (anti-BCMA) | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| BCMA CAR-NK (Shenzhen Pregene Biopharma) | Shenzhen Pregene Biopharma Co., Ltd. | allogeneic CAR-NK cell therapy | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech) | Chongqing Precision Biotech Co., Ltd | CAR-T cell therapy | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| Belantamab | GlaxoSmithKline | monoclonal antibody (non-conjugated) | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| Pamlectabart tismanitin | Heidelberg Pharma AG, Huadong Medicine | antibody-drug conjugate | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| SENL103 | Hebei Senlang Biotechnology | cell therapy (CAR-T) | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| Trovocabtagene autoleucel (C-CAR088) | AbelZeta Pharma, Inc. | CAR-T cell therapy | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| Zevorcabtagene autoleucel | CARsgen Therapeutics Holdings Limited, Hangzhou Zhongmei Huadong Pharmaceutical | cell therapy (autologous BCMA-targeted CAR-T) | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| ALLO-715 | Allogene Therapeutics, Inc. | cell therapy (allogeneic anti-BCMA CAR-T) | Phase 1 | Phase 1 in Multiple Myeloma |
| BCMA CAR-NK (Hrain) | Hrain Biotechnology Co., Ltd. | cell therapy (allogeneic BCMA-targeted CAR-NK) | Phase 1 | Phase 1 in Multiple Myeloma |
| BP2202 | BrightPath Biotherapeutics Co., Ltd. | cell therapy | Phase 1 | Phase 1 in Multiple Myeloma |
| CART-BCMA | Shanghai Simnova Biotechnology Co., Ltd. | CAR-T cell therapy | Phase 1 | Phase 1 in Multiple Myeloma |
| CBG002 | Zhejiang Carbiogene Therapeutics Co., Ltd. | CAR-T (autologous) | Phase 1 | Phase 1 in Multiple Myeloma |
| FT576 | Fate Therapeutics | cell therapy (allogeneic iPSC-derived CAR-NK) | Phase 1 | Phase 1 in Multiple Myeloma |
| IM21 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | CAR-T cell therapy | Phase 1 | Phase 1 in Multiple Myeloma |
| IMV102 | Suzhou Immunofoco Biotechnology Co., Ltd. | gene therapy (in vivo lentiviral CAR-T) | Phase 1 | Phase 1 in Multiple Myeloma |
| KLN-1010 | Kelonia Therapeutics, Inc. | gene therapy (in vivo lentiviral gene delivery) | Phase 1 | Phase 1 in Multiple Myeloma |
| P-BCMA-ALLO1 | Poseida Therapeutics, Inc. | cell therapy (allogeneic CAR-T) | Phase 1 | Phase 1 in Multiple Myeloma |
| UF-KURE-BCMA | Kure Cells, Inc. | CAR-T cell therapy (autologous, anti-BCMA) | Phase 1 | Phase 1 in Multiple Myeloma |
| UWD-00B | Wondercel Biotech (Shenzhen) Co., Ltd. | cell therapy (universal/allogeneic CAR-T) | Phase 1 | Phase 1 in Multiple Myeloma |
| BCMA-CART (Bioray Laboratories) | BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.) | CAR-T cell therapy | Stage not recorded | Not recorded |
| BRL-305 | BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.) | cell therapy (allogeneic CAR-T) | Stage not recorded | Not recorded |
| UTAA17 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | cell therapy (gamma-delta T CAR-T) | Stage not recorded | Not recorded |